93. HPV Vaccination in Males: Efficacy and Recommendations
Session: Mini-Symposium: Hot Topics in Sexually Transmitted Infections: Current Controversies
Friday, October 21, 2011: 7:30 AM
Room: 253ABC
Human papillomavirus (HPV) infections are the etiological agent for a variety of genital tract cancers in men and women including cervical, vulvar and anal cancers. In 2006, a quadrivalent vaccine was approved in the United States and recommended by the Advisory Committee on Immunization Practices (ACIP) for routine use in adolescent and young adult women. In 2010 and 2011, further research has shown that this vaccine prevents genital warts and anal cancer precursors in men. This lecture will discuss the recent literature and policy recommendations concerning wider use of this vaccine in men.

Kevin Ault, MD, FIDSA, Emory University School of Medicine, Atlanta, GA

Kevin Ault MD is a Associate Professor of Gynecology and Obstetrics at Emory University School of Medicine in Atlanta GA. Dr. Ault also participates as an investigator in the Emory Vaccine Center. Dr. Ault received his undergraduate degree from Butler University and his medical degree from Indiana University, both in Indianapolis IN. Dr. Ault did his residency in obstetrics and gynecology at Ohio State University, and received further training in infectious diseases at the University of Kansas. Dr. Ault's research clinical interests are infectious diseases and women's health. He has been an investigator in a wide variety of translational and clinical research involving vaginitis, gonorrhea, Chlamydia, herpes and human papillomavirus (HPV). He has also been involved in number of vacccine research projects involving women’s health, such as HPV vaccine development and immunology and maternal immunization. Dr. Ault is a fellow of the American College of Obstetricians and Gynecologists (ACOG) and a fellow of the Infectious Society of America. He has acted as liason representative to the ACIP on behalf of ACOG.

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.